Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
List view / Grid view
Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
A Swiss team have created a laboratory test that incorporates the placenta into embryotoxicity assessments without damaging foetuses.
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
In brain tissues, researchers have shown that two different nanosized polyoxoniobate molecules can inhibit the assembly of amyloid plaques.
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
Researchers have shown that the leakage of mitochondrial double-stranded DNA into the cell can contribute to Parkinson's disease.
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.